J Cancer 2017; 8(3):410-416. doi:10.7150/jca.17144 This issue Cite

Review

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor

Liting Guo, Haijun Zhang, Baoan Chen

Department of Hematology and Oncology (Key Department of Jiangsu Medicine), The Affiliated Zhongda Hospital, Medical School of Southeast University, Nanjing.

Citation:
Guo L, Zhang H, Chen B. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer 2017; 8(3):410-416. doi:10.7150/jca.17144. https://www.jcancer.org/v08p0410.htm
Other styles

File import instruction

Abstract

Targeted immunotherapy has become the most promising approach for tumor patients. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can reverse immune suppression and release T cell activation. Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and promotes antitumor immunity, and it is effective for treating non-small-cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC) and other cancers. The present review summarizes the efficacy and current status of clinical trials of nivolumab and that enabled nivolumab to be investigated in patients.

Keywords: nivolumab, programmed death-1 inhibitor, targeted immunotherapy.


Citation styles

APA
Guo, L., Zhang, H., Chen, B. (2017). Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. Journal of Cancer, 8(3), 410-416. https://doi.org/10.7150/jca.17144.

ACS
Guo, L.; Zhang, H.; Chen, B. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J. Cancer 2017, 8 (3), 410-416. DOI: 10.7150/jca.17144.

NLM
Guo L, Zhang H, Chen B. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer 2017; 8(3):410-416. doi:10.7150/jca.17144. https://www.jcancer.org/v08p0410.htm

CSE
Guo L, Zhang H, Chen B. 2017. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer. 8(3):410-416.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image